Copyright
©The Author(s) 2022.
World J Gastroenterol. Jul 21, 2022; 28(27): 3410-3421
Published online Jul 21, 2022. doi: 10.3748/wjg.v28.i27.3410
Published online Jul 21, 2022. doi: 10.3748/wjg.v28.i27.3410
Risk factors | Reported evidence | Ref. |
PNPLA3 | Carriage of rs738409 GG polymorphism is associated with 5.1–6.4-fold increased risk of HCC in NAFLD patients | [51-53,60] |
PNPLA3 G variant (GG vs CG vs CC) was not significantly associated with the risk of cardiovascular events extrahepatic cancers or overall death, but was associated with HCC (HR: 2.66) and liver-related death (HR: 2.42) | ||
Used for developing polygenic risk scores | ||
TM6SF2 | TM6SF2 minor allele carriage (rs58542926 C>T) was associated with advanced fibrosis/cirrhosis and HCC (OR, 2.8) in NAFLD patients | [54,55,60] |
Combined assessment with PNPLA3 and HSD17B13 variants were useful for risk stratification of NAFLD-HCC | ||
Used for developing polygenic risk scores | ||
MBOAT7 | MBOAT7 rs641738 C>T variants were associated with higher risk of HCC in NAFLD patients (OR, 1.65–2.10) | [56,60] |
Used for developing polygenic risk scores | ||
TLR5 | TLR5 rs5744174 TT genotype was a risk factor of HCC in patients with steatohepatitis-related cirrhosis (OR, 1.9) | [57] |
STAT6 | STAT6 rs167769 CC genotype was inversely associated with the risk of HCC in NASH patients (OR, 0.015) | [58] |
YAP1 | Carriage of YAP1 rs11225163 C allele was inversely associated with the risk of HCC in NASH patients (OR, 0.047) | [58] |
HSD17B13 | Combined assessment with PNPLA3 and TM6SF2 variants were useful for risk stratification of NAFLD-HCC | [55] |
DYSF | DYSF rs17007417 T allele carriage was associated with increased risk of HCC in NAFLD patients (OR, 2.74) | [59] |
GCKR | GCKR rs1260326 T allele carriage was associated with increased risk of HCC in NAFLD patients (OR, 1.38) | [59,60] |
Used for developing polygenic risk scores |
- Citation: Ueno M, Takeda H, Takai A, Seno H. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. World J Gastroenterol 2022; 28(27): 3410-3421
- URL: https://www.wjgnet.com/1007-9327/full/v28/i27/3410.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i27.3410